Article
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.
BMC cancer - 22 Nov 2025
Sendur Mehmet Ali Nahit, Hizal Mutlu, Çakar Burcu, Aktepe Oktay Halit, Eraslan Emrah, Arık Zafer, Erturk İsmail, Aksoy Sercan, Paydaş Semra, Değirmencioğlu Serkan, Erol Cihan, Demir Necla, Bulut Gülcan, Ak Naziye, Özkan Metin, Sevinç Alper, Özdemir Nuriye, Dişel Umut, Tural Deniz, Artaç Mehmet, Türk Hacı Mehmet, Menekşe Serkan, Göksu Sema Sezgin, Köse Fatih, Geredeli Cağlayan, Günaldı Meral, Uluç Başak Oyan, Şen Fatma, Oruç Kerem, Ölmez Ömer Fatih, Sakin Abdullah, Demirci Umut, Erdem Dilek, Ekinci Ferhat, Ökten Nihat, Özer Leyla, Okutur Kerem, Demir Atakan, Karadurmuş Nuri, Akıncı Muhammed Bülent, Yalçın Bülent, Gökmen Erhan
Abstract excerpt
INTRODUCTION: Talazoparib is a strong PARP inhibitor with significant catalytic inhibition as well as the ability to cause PARP entrapment at DNA damage sites. It is one of the recommended treatments for individuals with BRCA-mutant advanced breast cancer, although research on its efficacy in advanced ovarian cancer is limited. The purpose of this study was to evaluate the efficacy of talazoparib in advanced...
Topics
Join the communities discussing this publication.